Investigational Autism Drug Shows Preliminary Promise

The drug targets core autism symptoms and is currently available only through clinical trials or expanded access.

Updated on Oct. 28, 2026 in Autism

Several clear glass medical vials arranged neatly on a sterile stainless steel laboratory counter.
Yamo Pharmaceuticals is currently evaluating L1-79, an investigational oral therapy undergoing clinical trials to target social and communication challenges in autism spectrum disorder. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies prioritize developing new drug treatments for autism over existing behavioral therapies?

As of June 2026, families are exploring investigational options for autism spectrum disorder, including the experimental oral therapy L1-79. While no FDA-approved medication currently targets the core symptoms of autism, this drug is undergoing study to address socialization and communication.

Why it matters

With one in 31 children diagnosed with autism, researchers are investigating new ways to treat core challenges like communication and social interaction. Because no standard medications for these core symptoms currently exist, families and clinicians are closely tracking developments in ongoing trials.

Phase 2 trial results from a 12-week study indicated gains in socialization, communication, and speech patterns among participants. These preliminary findings are now being evaluated as the drug undergoes further regulatory review.

The players

Yamo Pharmaceuticals

A developer of investigational therapeutics focused on addressing the core symptoms of autism spectrum disorder.

FDA

The federal agency responsible for evaluating the safety and efficacy of new drugs and managing expanded-access programs.

The details

L1-79 is an investigational oral therapy designed to be administered twice daily. The drug functions by modulating specific brain signaling pathways associated with social interaction. Yamo Pharmaceuticals currently provides access to the therapy through clinical trials and an FDA expanded-access program.

Timeline

  1. Phase 2 results for the investigational drug were presented in 2025.

  2. A patient began treatment with the therapy in June 2026.

Health Landscape

The pursuit of L1-79 follows the FDA fast-track designation program, which is designed to expedite the review of drugs for serious conditions. This development reflects a broader research trend attempting to move beyond behavioral therapies toward interventions that target underlying brain signaling.

Families interested in emerging therapies should discuss the status of clinical trials and the FDA expanded-access program with their child's neurologist. It is important to remember that L1-79 is an investigational drug and is not currently an FDA-approved treatment.

The takeaway

While experimental therapies offer a new area of study, no FDA-approved medication exists to treat the core symptoms of autism. Families should prioritize ongoing, evidence-based behavioral care while discussing potential participation in clinical trials with a qualified specialist.

Further reading

Learn more about the latest research and clinical developments in our Autism section.

Source note: This article includes information reported by Juta MedicalBrief.

Live Poll

Should pharmaceutical companies prioritize developing new drug treatments for autism over existing behavioral therapies?